FDA Approves Unknown Drug — PAI HOLDINGS

PAI Holdings announced today that the FDA has approved the 1996-era ANDA referencing NDA058389, a development likely aimed at enhancing product availability and broadening market competition upon full launch. The approval of this long-studied asset allows the company to capture share from original brand products, providing a diversified revenue stream and mitigating reliance on newer pipeline candidates.